{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:40:24Z","timestamp":1789792824936,"version":"4.0.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T00:00:00Z","timestamp":1588032000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T00:00:00Z","timestamp":1588032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21474018"],"award-info":[{"award-number":["21474018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Exenatide is an insulinotropic peptide drug for type 2 diabetes treatment with low risk of hypoglycemia, and is administrated by subcutaneous injection. Oral administration is the most preferred route for lifelong treatment of diabetes, but oral delivery of peptide drug remains a significant challenge due to the absorption obstacles in gastrointestinal tract. We aimed to produce exenatide-loaded nanoparticles containing absorption enhancer, protectant and stabilizer using FDA approved inactive ingredients and easy to scale-up method, and to evaluate their long-term oral therapeutic effect in type 2 diabetes db\/db mice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Two types of nanoparticles, named COM NPs and DIS NPs, were fabricated using anti-solvent precipitation method. In COM NPs, the exenatide was complexed with cholic acid and phosphatidylcholine to increase the exenatide loading efficiency. In both nanoparticles, zein acted as the cement and the other ingredients were embedded in zein nanoparticles by hydrophobic interaction. Casein acted as the stabilizer. The nanoparticles had excellent lyophilization, storage and re-dispersion stability. Hypromellose phthalate protected the loaded exenatide from degradation in simulated gastric fluid. Cholic acid promoted the intestinal absorption of the loaded exenatide via bile acid transporters. The exenatide loading efficiencies of COM NPs and DIS NPs were 79.7% and 53.6%, respectively. The exenatide oral pharmacological availability of COM NPs was 18.6% and DIS NPs was 13.1%. COM NPs controlled the blood glucose level of the db\/db mice well and the HbA<jats:sub>1c<\/jats:sub> concentration significantly decreased to 6.8% during and after 7\u00a0weeks of once daily oral administration consecutively. Both DIS NPs and COM NPs oral groups substantially increased the insulin secretion by more than 60% and promoted the \u03b2-cell proliferation by more than 120% after the 7-week administration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Both COM NPs and DIS NPs are promising systems for oral delivery of exenatide, and COM NPs are better in blood glucose level control than DIS NPs. Using prolamin to produce multifunctional nanoparticles for oral delivery of peptide drug by hydrophobic interaction is a simple and effective strategy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12951-020-00619-0","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T17:02:36Z","timestamp":1588093356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Oral delivery of exenatide-loaded hybrid zein nanoparticles for stable blood glucose control and \u03b2-cell repair of type 2 diabetes mice"],"prefix":"10.1186","volume":"18","author":[{"given":"Xiaoyan","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7655-1739","authenticated-orcid":false,"given":"Ping","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,28]]},"reference":[{"key":"619_CR1","unstructured":"IDF Diabetes Atalas 9th edition. International Diabetes Federation, 2019. https:\/\/www.diabetesatlas.org\/en\/sections\/worldwide-toll-of-diabetes.html. Accessed 3 Jan 2020."},{"key":"619_CR2","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2337\/dc17-1144","volume":"42","author":"N Laiteerapong","year":"2019","unstructured":"Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the diabetes & aging study). Diabetes Care. 2019;42:416\u201326.","journal-title":"Diabetes Care"},{"key":"619_CR3","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1039\/C9MH00625G","volume":"6","author":"YF Xiao","year":"2019","unstructured":"Xiao YF, Hu Y, Du JZ. Controlling blood sugar levels with a glycopolymersome. Mat Horizons. 2019;6:2047\u201355.","journal-title":"Mat Horizons."},{"key":"619_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s13300-019-0572-z","volume":"10","author":"PJ Taylor","year":"2019","unstructured":"Taylor PJ, Thompson CH, Luscombe-Marsh ND, Wycherley TP, Wittert G, Brinkworth GD. Efficacy of real-time continuous glucose monitoring to improve effects of a prescriptive lifestyle intervention in type 2 diabetes: a pilot study. Diabetes Ther. 2019;10:509\u201322.","journal-title":"Diabetes Ther."},{"key":"619_CR5","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","volume":"2","author":"B Kreymann","year":"1987","unstructured":"Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2:1300\u20134.","journal-title":"Lancet."},{"key":"619_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.addr.2018.07.009","volume":"130","author":"M Yu","year":"2018","unstructured":"Yu M, Benjamin MM, Srinivasan S, Morin EE, Shishatskaya EI, Schwendeman SP, et al. Battle of GLP-1 delivery technologies. Adv Drug Deliv Rev. 2018;130:113\u201330.","journal-title":"Adv Drug Deliv Rev"},{"key":"619_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jconrel.2019.03.014","volume":"301","author":"Z He","year":"2019","unstructured":"He Z, Hu Y, Gui Z, Zhou Y, Nie T, Zhu J, et al. Sustained release of exendin-4 from tannic acid\/Fe(III) nanoparticles prolongs blood glycemic control in a mouse model of type II diabetes. J Control Release. 2019;301:119\u201328.","journal-title":"J Control Release"},{"key":"619_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1067\/mpd.2002.122470","volume":"140","author":"R Hanas","year":"2002","unstructured":"Hanas R, Adolfsson P, Elfvin-Akesson K, Hammaren L, Ilvered R, Jansson I, et al. Indwelling catheters used from the onset of diabetes decrease injection pain and pre-injection anxiety. J Pediatr. 2002;140:315\u201320.","journal-title":"J Pediatr"},{"key":"619_CR9","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/pharmaceutics11080418","volume":"11","author":"MM Abeer","year":"2019","unstructured":"Abeer MM, Meka AK, Pujara N, Kumeria T, Strounina E, Nunes R, et al. Rationally designed dendritic silica nanoparticles for oral delivery of exenatide. Pharmaceutics. 2019;11:418.","journal-title":"Pharmaceutics."},{"key":"619_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.addr.2016.10.005","volume":"106","author":"DJ Brayden","year":"2016","unstructured":"Brayden DJ, Alonso M-J. Oral delivery of peptides: opportunities and issues for translation. Adv Drug Deliv Rev. 2016;106:193\u20135.","journal-title":"Adv Drug Deliv Rev"},{"key":"619_CR11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.addr.2016.02.011","volume":"106","author":"HR Lakkireddy","year":"2016","unstructured":"Lakkireddy HR, Urmann M, Besenius M, Werner U, Haack T, Brun P, et al. Oral delivery of diabetes peptides\u2014comparing standard formulations incorporating functional excipients and nanotechnologies in the translational context. Adv Drug Deliv Rev. 2016;106:196\u2013222.","journal-title":"Adv Drug Deliv Rev"},{"key":"619_CR12","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1517\/17425247.2016.1151872","volume":"13","author":"S Rao","year":"2016","unstructured":"Rao S, Prestidge CA. Polymer-lipid hybrid systems: merging the benefits of polymeric and lipid-based nanocarriers to improve oral drug delivery. Expert Opin Drug Deliv. 2016;13:691\u2013707.","journal-title":"Expert Opin Drug Deliv."},{"key":"619_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.biomaterials.2017.03.028","volume":"130","author":"Z He","year":"2017","unstructured":"He Z, Santos JL, Tian H, Huang H, Hu Y, Liu L, et al. Scalable fabrication of size-controlled chitosan nanoparticles for oral delivery of insulin. Biomaterials. 2017;130:28\u201341.","journal-title":"Biomaterials"},{"key":"619_CR14","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1039\/C8BM01485J","volume":"7","author":"F Guo","year":"2019","unstructured":"Guo F, Ouyang T, Peng T, Zhang X, Xie B, Yang X, et al. Enhanced oral absorption of insulin using colon-specific nanoparticles co-modified with amphiphilic chitosan derivatives and cell-penetrating peptides. Biomater Sci. 2019;7:1493\u2013506.","journal-title":"Biomater Sci."},{"key":"619_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jconrel.2015.09.012","volume":"217","author":"L Soudry-Kochavi","year":"2015","unstructured":"Soudry-Kochavi L, Naraykin N, Nassar T, Benita S. Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach. J Control Release. 2015;217:202\u201310.","journal-title":"J Control Release"},{"key":"619_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12951-015-0136-y","volume":"13","author":"G Sharma","year":"2015","unstructured":"Sharma G, Sharma AR, Nam J-S, Doss GPC, Lee S-S, Chakraborty C. Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes. J Nanobiotechnol. 2015;13:74.","journal-title":"J Nanobiotechnol."},{"key":"619_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/chem.202000773","author":"E Juere","year":"2020","unstructured":"Juere E, Caillard R, Marko D, Favero G, Kleitz F. Smart protein\u2010based formulation of dendritic mesoporous silica nanoparticles: toward oral delivery of insulin. Chemi\u2013A Eur J. 2020. https:\/\/doi.org\/10.1002\/chem.202000773.","journal-title":"Chemi\u2013A Eur J."},{"key":"619_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41551-019-0465-5","volume":"4","author":"NG Lamson","year":"2020","unstructured":"Lamson NG, Berger A, Fein KC, Whitehead KA. Anionic nanoparticles enable the oral delivery of proteins by enhancing intestinal permeability. Nat Biomed Eng. 2020;4:84\u201396.","journal-title":"Nat Biomed Eng."},{"key":"619_CR19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4155\/tde.14.111","volume":"6","author":"AL Lewis","year":"2015","unstructured":"Lewis AL, Richard J. Challenges in the delivery of peptide drugs: an industry perspective. Ther Deliv. 2015;6:149\u201363.","journal-title":"Ther Deliv."},{"key":"619_CR20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jconrel.2012.12.013","volume":"166","author":"S Naahidi","year":"2013","unstructured":"Naahidi S, Jafari M, Edalat F, Raymond K, Khademhosseini A, Chen P. Biocompatibility of engineered nanoparticles for drug delivery. J Control Release. 2013;166:182\u201394.","journal-title":"J Control Release"},{"key":"619_CR21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1504\/IJNT.2009.024647","volume":"6","author":"T Tsuzuki","year":"2009","unstructured":"Tsuzuki T. Commercial scale production of inorganic nanoparticles. Int J Nanotechnol. 2009;6:567\u201378.","journal-title":"Int J Nanotechnol"},{"key":"619_CR22","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1080\/10717544.2018.1469685","volume":"25","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Li H, Xu G, Yao P. Liver-targeted delivery of insulin-loaded nanoparticles via enterohepatic circulation of bile acids. Drug Deliv. 2018;25:1224\u201333.","journal-title":"Drug Deliv."},{"key":"619_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.autrev.2015.01.009","volume":"14","author":"A Lerner","year":"2015","unstructured":"Lerner A, Matthias T. Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease. Autoimmun Rev. 2015;14:479\u201389.","journal-title":"Autoimmun Rev"},{"key":"619_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00795-003-0219-y","volume":"36","author":"N Sawada","year":"2003","unstructured":"Sawada N, Murata M, Kikuchi K, Osanai M, Tobioka H, Kojima T, et al. Tight junctions and human diseases. Med Electron Microsc. 2003;36:147\u201356.","journal-title":"Med Electron Microsc."},{"key":"619_CR25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0926-6690(00)00064-9","volume":"13","author":"R Shukla","year":"2001","unstructured":"Shukla R, Cheryan M. Zein: the industrial protein from corn. Ind Crops Prod. 2001;13:171\u201392.","journal-title":"Ind Crops Prod"},{"key":"619_CR26","doi-asserted-by":"publisher","first-page":"5933","DOI":"10.1039\/c3sm50667c","volume":"9","author":"F Dong","year":"2013","unstructured":"Dong F, Padua GW, Wang Y. Controlled formation of hydrophobic surfaces by self-assembly of an amphiphilic natural protein from aqueous solutions. Soft Matter. 2013;9:5933\u201341.","journal-title":"Soft Matter"},{"key":"619_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/17425247.2017.1349752","volume":"15","author":"G Labib","year":"2018","unstructured":"Labib G. Overview on zein protein: a promising pharmaceutical excipient in drug delivery systems and tissue engineering. Expert Opin Drug Deliv. 2018;15:65\u201375.","journal-title":"Expert Opin Drug Deliv."},{"key":"619_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1477-3155-10-44","volume":"10","author":"MC Regier","year":"2012","unstructured":"Regier MC, Taylor JD, Borcyk T, Yang Y, Pannier AK. Fabrication and characterization of DNA-loaded zein nanospheres. J Nanobiotechnol. 2012;10:44.","journal-title":"J Nanobiotechnol."},{"key":"619_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2019.10.006","volume":"313","author":"N Ji","year":"2019","unstructured":"Ji N, Hong Y, Gu Z, Cheng L, Li Z, Li C. Chitosan coating of zein-carboxymethylated short-chain amylose nanocomposites improves oral bioavailability of insulin in vitro and in vivo. J Control Release. 2019;313:1\u201313.","journal-title":"J Control Release"},{"key":"619_CR30","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.biomaterials.2011.10.072","volume":"33","author":"Q Peng","year":"2012","unstructured":"Peng Q, Zhang ZR, Gong T, Chen GQ, Sun X. A rapid-acting, long-acting insulin formulation based on a phospholipid complex loaded PHBHHx nanoparticles. Biomaterials. 2012;33:1583\u20138.","journal-title":"Biomaterials"},{"key":"619_CR31","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2147\/IJN.S96146","volume":"11","author":"L Liu","year":"2016","unstructured":"Liu L, Zhou C, Xia X, Liu Y. Self-assembled lecithin\/chitosan nanoparticles for oral insulin delivery: preparation and functional evaluation. Int J Nanomed. 2016;11:761\u20139.","journal-title":"Int J Nanomed."},{"key":"619_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/10717540500313109","volume":"13","author":"A \u010cilek","year":"2006","unstructured":"\u010cilek A, \u010celebi N, Tirnaksiz F. Lecithin-based microemulsion of a peptide for oral administration: preparation, characterization, and physical stability of the formulation. Drug Deliv. 2006;13:19\u201324.","journal-title":"Drug Deliv."},{"key":"619_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1172\/JCI108465","volume":"58","author":"H Westergaard","year":"1976","unstructured":"Westergaard H, Dietschy JM. The mechanism whereby bile acid micelles increase the rate of fatty acid and cholesterol uptake into the intestinal mucosal cell. J Clin Invest. 1976;58:97\u2013108.","journal-title":"J Clin Invest."},{"key":"619_CR34","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1172\/JCI106931","volume":"51","author":"ER Schiff","year":"1972","unstructured":"Schiff ER, Small NC, Dietschy JM. Characterization of the kinetics of the passive and active transport mechanisms for bile acid absorption in the small intestine and colon of the rat. J Clin Invest. 1972;51:1351\u201362.","journal-title":"J Clin Invest."},{"key":"619_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.biomaterials.2017.10.022","volume":"151","author":"W Fan","year":"2018","unstructured":"Fan W, Xia D, Zhu Q, Li X, He S, Zhu C, et al. Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery. Biomaterials. 2018;151:13\u201323.","journal-title":"Biomaterials"},{"key":"619_CR36","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jconrel.2018.12.028","volume":"294","author":"K Suzuki","year":"2019","unstructured":"Suzuki K, Kim KS, Bae YH. Long-term oral administration of Exendin-4 to control type 2 diabetes in a rat model. J Control Release. 2019;294:259\u201367.","journal-title":"J Control Release"},{"key":"619_CR37","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ejps.2010.12.007","volume":"42","author":"A Makhlof","year":"2011","unstructured":"Makhlof A, Tozuka Y, Takeuchi H. Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery. Eur J Pharm Sci. 2011;42:445\u201351.","journal-title":"Eur J Pharm Sci"},{"key":"619_CR38","first-page":"1","volume":"13","author":"S Zhang","year":"2018","unstructured":"Zhang S, Han Y. Preparation, characterisation and antioxidant activities of rutin-loaded zein-sodium caseinate nanoparticles. PLoS ONE. 2018;13:1\u201313.","journal-title":"PLoS ONE"},{"key":"619_CR39","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1021\/acs.molpharmaceut.6b00188","volume":"13","author":"Z Zhang","year":"2016","unstructured":"Zhang Z, Cai H, Liu Z, Yao P. Effective enhancement of hypoglycemic effect of insulin by liver-targeted nanoparticles containing cholic acid-modified chitosan derivative. Mol Pharm. 2016;13:2433\u201342.","journal-title":"Mol Pharm"},{"key":"619_CR40","doi-asserted-by":"publisher","first-page":"9678","DOI":"10.1016\/j.biomaterials.2013.08.048","volume":"34","author":"X Li","year":"2013","unstructured":"Li X, Guo S, Zhu C, Zhu Q, Gan Y, Rantanen J, et al. Intestinal mucosa permeability following oral insulin delivery using core shell corona nanolipoparticles. Biomaterials. 2013;34:9678\u201387.","journal-title":"Biomaterials"},{"key":"619_CR41","first-page":"1","volume":"2012","author":"Y Zhong","year":"2012","unstructured":"Zhong Y, Wang J, Gu P, Shao J, Lu B, Jiang S. Effect of ezetimibe on insulin secretion in db\/db diabetic mice. Exp Diabetes Res. 2012;2012:1\u20136.","journal-title":"Exp Diabetes Res."},{"key":"619_CR42","doi-asserted-by":"publisher","first-page":"30703","DOI":"10.1021\/acsami.6b09415","volume":"8","author":"Y Chen","year":"2016","unstructured":"Chen Y, Luan J, Shen W, Lei K, Yu L, Ding J. Injectable and thermosensitive hydrogel containing liraglutide as a long-acting antidiabetic system. ACS Appl Mater Interfaces. 2016;8:30703\u201313.","journal-title":"ACS Appl Mater Interfaces"},{"key":"619_CR43","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1016\/S0032-3861(00)00837-5","volume":"42","author":"A Benrebouh","year":"2001","unstructured":"Benrebouh A, Avoce D, Zhu X. Thermo-and pH-sensitive polymers containing cholic acid derivatives. Polymer. 2001;42:4031\u20138.","journal-title":"Polymer"},{"key":"619_CR44","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.cocis.2014.08.001","volume":"19","author":"AR Patel","year":"2014","unstructured":"Patel AR, Velikov KP. Zein as a source of functional colloidal nano- and microstructures. Curr Opin Colloid In. 2014;19:450\u20138.","journal-title":"Curr Opin Colloid In."},{"key":"619_CR45","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ijpharm.2016.10.023","volume":"515","author":"S Lee","year":"2016","unstructured":"Lee S, Kim YC, Park JH. Zein-alginate based oral drug delivery systems: Protection and release of therapeutic proteins. Int J Pharm. 2016;515:300\u20136.","journal-title":"Int J Pharm"},{"key":"619_CR46","doi-asserted-by":"publisher","first-page":"12497","DOI":"10.1021\/jf102959b","volume":"58","author":"AR Patel","year":"2010","unstructured":"Patel AR, Bouwens ECM, Velikov KP. Sodium caseinate stabilized zein colloidal particles. J Agric Food Chem. 2010;58:12497\u2013503.","journal-title":"J Agric Food Chem"},{"key":"619_CR47","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.addr.2016.04.014","volume":"106","author":"A Beloqui","year":"2016","unstructured":"Beloqui A, des Rieux A, Preat V. Mechanisms of transport of polymeric and lipidic nanoparticles across the intestinal barrier. Adv Drug Deliv Rev. 2016;106:242\u201355.","journal-title":"Adv Drug Deliv Rev."},{"key":"619_CR48","doi-asserted-by":"publisher","first-page":"5929","DOI":"10.1021\/acsami.6b00821","volume":"8","author":"GH Chai","year":"2016","unstructured":"Chai GH, Xu YK, Chen SQ, Cheng BL, Hu FQ, You JA, et al. Transport mechanisms of solid lipid nanoparticles across caco-2 cell monolayers and their related cytotoxicology. ACS Appl Mater Interfaces. 2016;8:5929\u201340.","journal-title":"ACS Appl Mater Interfaces"},{"key":"619_CR49","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1021\/nn304439f","volume":"7","author":"H Herd","year":"2013","unstructured":"Herd H, Daum N, Jones AT, Huwer H, Ghandehari H, Lehr CM. Nanoparticle geometry and surface orientation influence mode of cellular uptake. ACS Nano. 2013;7:1961\u201373.","journal-title":"ACS Nano"},{"key":"619_CR50","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jconrel.2016.04.012","volume":"232","author":"M Lopes","year":"2016","unstructured":"Lopes M, Shrestha N, Correia A, Shahbazi MA, Sarmento B, Hirvonen J, et al. Dual chitosan\/albumin-coated alginate\/dextran sulfate nanoparticles for enhanced oral delivery of insulin. J Control Release. 2016;232:29\u201341.","journal-title":"J Control Release"},{"key":"619_CR51","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jconrel.2009.08.010","volume":"140","author":"E Roger","year":"2009","unstructured":"Roger E, Lagarce F, Garcion E, Benoit JP. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J Control Release. 2009;140:174\u201381.","journal-title":"J Control Release"},{"key":"619_CR52","doi-asserted-by":"publisher","first-page":"9199","DOI":"10.1016\/j.biomaterials.2014.07.026","volume":"35","author":"F Araujo","year":"2014","unstructured":"Araujo F, Shrestha N, Shahbazi MA, Fonte P, Makila EM, Salonen JJ, et al. The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium. Biomaterials. 2014;35:9199\u2013207.","journal-title":"Biomaterials"},{"key":"619_CR53","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1016\/j.biomaterials.2010.12.044","volume":"32","author":"HN Nguyen","year":"2011","unstructured":"Nguyen HN, Wey SP, Juang JH, Sonaje K, Ho YC, Chuang EY, et al. The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo. Biomaterials. 2011;32:2673\u201382.","journal-title":"Biomaterials"},{"key":"619_CR54","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ijpharm.2008.01.015","volume":"356","author":"BR Gedulin","year":"2008","unstructured":"Gedulin BR, Smith PA, Jodka CM, Chen K, Bhavsar S, Nielsen LL, et al. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int J Pharm. 2008;356:231\u20138.","journal-title":"Int J Pharm"},{"key":"619_CR55","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1055\/s-2005-870529","volume":"37","author":"K Taylor","year":"2005","unstructured":"Taylor K, Kim D, Nielsen LL, Aisporna M, Baron AD, Fineman MS. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes. Horm Metab Res. 2005;37:627\u201332.","journal-title":"Horm Metab Res"},{"key":"619_CR56","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1093\/clinchem\/47.7.1157","volume":"47","author":"U Krishnamurti","year":"2001","unstructured":"Krishnamurti U, Steffes MW. Glycohemoglobin: a primary predictor of the development or reversal of complications of diabetes mellitus. Clin Chem. 2001;47:1157\u201365.","journal-title":"Clin Chem"},{"key":"619_CR57","doi-asserted-by":"publisher","first-page":"368","DOI":"10.2337\/diab.41.3.368","volume":"41","author":"E Van Cauter","year":"1992","unstructured":"Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes. 1992;41:368\u201377.","journal-title":"Diabetes"},{"key":"619_CR58","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131\u201357.","journal-title":"Gastroenterology"},{"key":"619_CR59","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1177\/193229681000400629","volume":"4","author":"R Eldor","year":"2010","unstructured":"Eldor R, Kidron M, Greenberg-Shushlav Y, Arbit E. Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models. J Diabetes Sci Technol. 2010;4:1516\u201323.","journal-title":"J Diabetes Sci Technol."}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-020-00619-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-020-00619-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-020-00619-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T23:48:18Z","timestamp":1619567298000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-020-00619-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,28]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["619"],"URL":"https:\/\/doi.org\/10.1186\/s12951-020-00619-0","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,28]]},"assertion":[{"value":"14 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments of this study were carried out at Experimental Animal Center, School of Pharmacy, Fudan University, and were approved by Experimental Animal Ethics Committee of School of Pharmacy, Fudan University. Consent to participate: Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}